Precede Biosciences
Precede Biosciences develops and operates a comprehensive epigenomic liquid biopsy platform that profiles transcriptional biology from cell-free DNA in plasma. The company combines wet‑lab assays, bioinformatics, and machine learning to infer genome‑wide gene expression, pathway activity, and cell states from small plasma volumes (reported from 1 mL), and offers research and clinical‑trial focused services to support drug development and diagnostics.
Industries
Nr. of Employees
small (1-50)
Precede Biosciences
Products
Genome‑wide functional liquid biopsy (research‑use product)
A research‑use liquid biopsy assay and analytical workflow that infers gene expression, pathway activity, and cell states genome‑wide from cfDNA in plasma; designed for R&D and translational applications.
Clinical‑trial focused liquid biopsy service for non‑invasive patient selection
A service offering designed to support clinical trials with non‑invasive assays for target expression, pathway activity, and cell‑state assessment to inform enrollment and treatment strategies.
Precede Biosciences Epigenomic Liquid Biopsy Platform
A first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, providing resolution into gene promoters, enhancers, and CpG islands.
Genome‑wide functional liquid biopsy (research‑use product)
A research‑use liquid biopsy assay and analytical workflow that infers gene expression, pathway activity, and cell states genome‑wide from cfDNA in plasma; designed for R&D and translational applications.
Clinical‑trial focused liquid biopsy service for non‑invasive patient selection
A service offering designed to support clinical trials with non‑invasive assays for target expression, pathway activity, and cell‑state assessment to inform enrollment and treatment strategies.
Precede Biosciences Epigenomic Liquid Biopsy Platform
A first-in-class comprehensive epigenomic liquid biopsy platform that profiles circulating chromatin and the DNA methylome from just 1mL of plasma, providing resolution into gene promoters, enhancers, and CpG islands.
Services
Research collaborations to generate genome‑wide quantitative profiles of gene expression, pathway activity, and cell states from plasma for drug development and translational research.
Services to support clinical trials including non‑invasive patient selection based on target expression and pathway activity, pharmacodynamic monitoring, and stratification for emerging targeted modalities.
Research collaborations to generate genome‑wide quantitative profiles of gene expression, pathway activity, and cell states from plasma for drug development and translational research.
Services to support clinical trials including non‑invasive patient selection based on target expression and pathway activity, pharmacodynamic monitoring, and stratification for emerging targeted modalities.
Expertise Areas
- Liquid biopsy epigenomics
- cfDNA‑based inference of gene expression
- Translational biomarker development
- Computational biology and bioinformatics
Key Technologies
- Comprehensive cfDNA epigenomic profiling
- Liquid biopsy (plasma‑based)
- Next‑generation sequencing (NGS)
- Machine learning for biological inference
News & Updates
Company announced $63.5M Series B equity and a $20M strategic credit facility to scale its epigenomic liquid biopsy platform and meet growing demand from developers of next‑generation precision medicines.
Launch of a research‑use product enabling genome‑wide inference of gene expression, pathway activity, and cell states from 1 mL plasma, with supporting AACR 2026 data.
Data showing assessment of MET expression, pathway activity, and lineage plasticity from 1 mL plasma with high concordance to tissue measures in EGFR‑mutated NSCLC.
Presentation demonstrating prediction of expression for thousands of tumor‑specific genes from 1 mL plasma to inform therapeutic decision‑making.
Peer‑reviewed publication describing use of epigenomic liquid biopsy for cancer subtyping (presented in company materials).
Company announced $63.5M Series B equity and a $20M strategic credit facility to scale its epigenomic liquid biopsy platform and meet growing demand from developers of next‑generation precision medicines.
Launch of a research‑use product enabling genome‑wide inference of gene expression, pathway activity, and cell states from 1 mL plasma, with supporting AACR 2026 data.
Data showing assessment of MET expression, pathway activity, and lineage plasticity from 1 mL plasma with high concordance to tissue measures in EGFR‑mutated NSCLC.
Presentation demonstrating prediction of expression for thousands of tumor‑specific genes from 1 mL plasma to inform therapeutic decision‑making.
Peer‑reviewed publication describing use of epigenomic liquid biopsy for cancer subtyping (presented in company materials).